A.L.P.S. Clavicle Plating System PMCF

N/AActive Not RecruitingNCT05327959

Zimmer Biomet98 enrolled

Overview

A commercially available product clinical study which aims to confirm the safety, performance, and clinical benefits to the patient of the ALPS Clavicle Plating system for both the implant itself and the instrumentation used during surgery.

The objectives of this observational, prospective study with optional retrospective enrollment are to confirm safety, performance and clinical benefits of the A.L.P.S Clavicle Plating System and its instrumentation by analysis of fracture healing, functional outcome and adverse events. The safety of the system will be assessed by monitoring the frequency and incidence of adverse events including re-operations. Relation of the events to implant, instrumentation and/or procedure should be specified. The performance will be evaluated by assessment of fracture/osteotomy healing and functional outcome of all enrolled study subjects.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Clavicle Fracture Clavicle Injury

Interventions

Clavicle open reduction and internal fixationDEVICE

Clavicle open reduction and internal fixation using the A.L.P.S. Clavicle Plating System

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Patient must be 18 years of age or older. * Patient must have a clavicle fracture requiring surgical intervention and be eligible for fixation by locking plate and screws. * Unilateral or Bilateral fractures. * Patient must be capable of understanding the doctor's explanation, following doctor's instruction, is able to and willing to complete the protocol required follow-up. * Patient must have a signed IRB/EC approved informed consent. Exclusion Criteria: * Active infection. * Patients presenting conditions including blood supply limitations, insufficient quantity or quality of bone. * Patients with mental or neurologic conditions who are unwilling or incapable of giving proper informed consent, following postoperative care instructions. * Foreign body sensitivity where material sensitivity is suspected, testing is to be completed prior to implantation of the device. * Patient is a current alcohol or drug abuser * Patient is a prisoner * Patient known to be pregnant or breast feeding * Likely problems with maintaining follow-up program (e.g. patient with no fixed address, long distance, plans to move during course of study) * Not expected to survive the duration of the follow-up program

Locations (5)

Cleveland Clinic Florida

Weston, Florida, United States

University of Michigan - Michigan Medicine

Ann Arbor, Michigan, United States

Slocum Research & Education Foundation

Eugene, Oregon, United States

University of Texas San Antonio

San Antonio, Texas, United States

Outcomes

Primary Outcomes

Number of subjects with fracture healing

Number of subjects with fracture healing will be assessed through 12 months follow-up. Radiologic fracture healing is defined as: Bridging callus or no visible fracture lines on AP and 15-45° cephalic oblique radiographs.

Time frame: 12 months

Secondary Outcomes

Frequency and Incidence of Adverse Events (Safety)

Monitoring the frequency and incidence of adverse events, serious adverse events, adverse device effects, serious adverse device effects, and unanticipated serious adverse device effects as well as device deficiencies.

Time frame: 12 months

Range of Motion - Total shoulder motion

Range of Motion (affected and contralateral), Forward elevation (maximum arm-trunk angle), External rotation (arm comfortably at side), External rotation (arm at 90 degrees of abduction), Internal rotation (thumb to back) spinous process, Cross-body adduction (antecubital fossa to opposite acromion (cm)

Time frame: 12 months

Clinical efficacy of the device is assessed using the American Shoulder and Elbow Surgeons (ASES) Shoulder Score at 12 months follow-up

The ASES scale is 0-100. 100 is the highest score and indicates the greatest function while 0 is the lowest score.

Time frame: 12 months

Euroqol Patient Quality of life measured at 12 months follow-up (EQ-5D-5L)

The EuroQol five dimensions questionnaire (EQ-5D-5L) is a five dimensional self-assessment that is comprised of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. These five dimensions can be used to index a subject's health utility on a scale of 0 to 1, where 0 is death and 1 is perfect health. The scoring rule for EQ-5D permits scores less than 0, implying that some health states may be worse than death.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.